Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění?

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Title in English Chimeric Antigen Receptor T-cells- Gene Therapy of the Future for Malignant Diseases?
Authors

ŠMÍDA Michal

Year of publication 2015
Type Article in Periodical
Magazine / Source Klinická onkologie: časopis České a Slovenské onkologické společnosti
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.prolekare.cz/klinicka-onkologie-clanek/chimericky-antigenni-receptor-t-lymfocytu-genova-terapie-budoucnosti-u-nadorovych-onemocneni-56682?confirm_rules=1
Doi http://dx.doi.org/10.14735/amko20154S44
Field Oncology and hematology
Keywords gene therapy; genetics; human; immunology; metabolism; Neoplasms; T lymphocyte
Attached files
Description Chimeric antigen receptors are synthetic, genetically modified receptors of T-cells. The introduction of chimeric antigen receptors into autologous patient T-cells can redirect the lymphocytes to specific antigen targets on the surface of malignant cells. This has recently emerged as an intriguing therapy approach in both hematologic malignancies and later also in solid tumors. Various chimeric antigen receptor designs and manufacturing processes were developed and seem to have a strong impact on the activity of chimeric antigen receptor T-lymphocytes and thereby the therapy success. The individual variables are currently being tested in numerous clinical trials. In this review, I will briefly describe the principle, basic structure and construction of chimeric antigen receptor T-lymphocytes.

You are running an old browser version. We recommend updating your browser to its latest version.

More info